On Thursday, Bristol Myers Squibb (BMY) stock got a positive adjustment to its Relative Strength (RS) Rating, from 80 to 83.
↑ XIBD's proprietary rating tracks price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Bristol Myers Squibb stock is building a with a 61.08 entry. See if it can break out in heavy trading. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The drug maker posted -10% earnings growth in its most recent report. Sales rose 8%.
Bristol Myers Squibb stock earns the No. 3 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health (PAHC) is the top-ranked stock within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
YOU MAY ALSO LIKE:
Learn How To Time The Market With IBD's ETF Market Strategy
Find Today's Best Growth Stocks To Watch With IBD 50
Find The Best Long-Term Investments With IBD Long-Term Leaders
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。